RPTPα De-clustering via Antibody Binding for Cell Migration Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating arthritis, fibrosis, and cancer have not effectively addressed the role of RPTPα clustering, with existing understanding suggesting dimerization-induced inhibition, whereas RPTPα clustering is found to have a stimulatory role, and de-clustering is necessary for functional inhibition.
Innovation Solution
The use of monoclonal antibodies and recombinant polypeptides that target RPTPα to de-cluster RPTPα, reducing its association with SRC, thereby inhibiting cell migration and treating autoimmune diseases, fibrosis, and cancer by administering an RPTPα antagonist, such as an anti-RPTPα antibody or a recombinant polypeptide that causes de-clustering.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If RPTPα dimerization is induced to inhibit RPTPα function, then RPTPα activity is reduced, but the mechanism is incorrect as clustering actually stimulates RPTPα function
Solution Approach 1:
The patent inverts the conventional understanding by demonstrating that RPTPα clustering has a stimulatory rather than inhibitory role on RPTPα function. This inversion resolves the contradiction by showing that the traditional dimerization-induced inhibition model is incorrect for RPTPα, and that clustering actually activates the enzyme, necessitating a different therapeutic approach.
Solution Approach 2:
The patent converts the harmful effect of RPTPα clustering (which stimulates excessive cell migration in disease) into a beneficial therapeutic target by developing antibodies that specifically bind to clustered RPTPα. By targeting the clustered form rather than preventing clustering, the therapy exploits the clustering phenomenon itself to achieve selective inhibition of pathological RPTPα activity while potentially sparing non-clustered physiological functions.
2Reliability
If monoclonal antibody binds to RPTPα to de-cluster it, then RPTPα association with SRC is reduced, but the mechanism differs from traditional cross-linking inhibition
Solution Approach 1:
The patent extracts the extracellular domain of RPTPα as the specific target for antibody binding. By designing monoclonal antibodies that bind to epitopes in the extracellular domain, the therapy selectively disrupts RPTPα clustering and its association with SRC without affecting the intracellular catalytic domains, thereby achieving specific inhibition of the pathological signaling complex.
Solution Approach 2:
The patent uses monoclonal antibodies as intermediary molecules that mediate the disruption of RPTPα clustering. These antibodies serve as a bridge between the therapeutic agent and the target protein, binding to clustered RPTPα and inducing conformational changes or steric hindrance that prevent SRC recruitment and activate RPTPα's phosphatase activity, thereby inhibiting downstream signaling.
3Reliability
If RPTPα clustering is promoted to inhibit RPTPα activity, then functional inhibition is achieved, but this contradicts the stimulatory role of clustering
Solution Approach 1:
The patent employs preliminary action by administering monoclonal antibodies that pre-bind to clustered RPTPα before the pathological signaling can occur. This preventive binding disrupts the formation of the RPTPα-SRC signaling complex and activates RPTPα phosphatase activity in advance, preventing excessive cell migration and disease progression rather than attempting to reverse it.
Solution Approach 2:
The patent changes the functional state of RPTPα by inducing de-clustering through antibody binding. This parameter change transforms RPTPα from a clustered, SRC-associated, potentially inactive state to a de-clustered, activated phosphatase state, thereby reversing the stimulatory effect of clustering and achieving functional inhibition of the pathological signaling pathway.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
De-clustering RPTPα leads to effective inhibition of cell migration and disease progression in arthritis, fibrosis, and cancer, demonstrating that RPTPα clustering is stimulatory rather than inhibitory, and providing a therapeutic approach by reducing RPTPα activity.
Implementation Method 1
incubation of FLS with a monoclonal antibody (Mab-2F8) developed against the extracellular domain of RPTPα results in RPTPα-dependent inhibition of cell migration. The inhibition of cell migration correlated with Mab-2F8-mediated de-clustering of RPTPα and a reduced association between RPTPα and SRC
Implementation Method 2
acceptor photobleaching (AP) fluorescence resonance energy transfer (FRET) microscopy-based assays
Data Source
AI summary
Described herein are methods and compositions to treat arthritis, fibrosis and cancer by inhibiting RPTPα clustering. Included are methods and compositions for the diagnosis of RPTPα clustering.